ON101, Oneness Biotech’s innovative treatment for diabetic foot ulcers, has been selected among the Global Top 15 in the American Diabetes Association (ADA) 2026 Innovation Challenge, emerging as one of only 15 selected entries from a highly competitive global applicant pool.
The ADA Innovation Challenge is a premier innovation competition held during the ADA Scientific Sessions, recognizing breakthrough technologies and therapeutic solutions with strong clinical value and market potential in diabetes care. ADA Scientific Sessions is one of the world’s most influential diabetes conferences, attracting more than 12,000 endocrinologists, researchers, diabetes care specialists, and healthcare industry leaders from around the globe each year.
This recognition highlights the international validation of ON101’s innovative mechanism, clinical value, and potential to address unmet needs in diabetic foot ulcer treatment. In addition, Oneness Biotech has been invited to present at the Innovation Hub during ADA 2026 Scientific Sessions, where the company will share ON101’s clinical achievements and real-world application value with global diabetes experts, physicians, and potential partners.
Being named among the Global Top 15 not only strengthens ON101’s international visibility in diabetes and wound care, but also underscores Oneness Biotech’s innovation capabilities in chronic wound management. The recognition further supports the company’s efforts to expand global market opportunities and deepen international clinical and commercial collaborations.